SAVIMS

SAVIMS logo white
Menu

Epidemiological surveillance

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Understanding RRR and ARR in Vaccine Trials

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Reference: Iriarte, I., & Phoenix, S. (2021). Understanding relative risk reduction (RRR) and absolute risk reduction (ARR) in vaccine trials. PANDA. https://www.pandata.org/understanding-relative-risk-reduction-and-absolute-risk-reduction-in-vaccine-trials/ Summary: The article discusses the critical distinctions between Relative Risk Reduction (RRR) and Absolute Risk Reduction (ARR) in the context of vaccine trials, particularly those for COVID-19. RRR compares the efficacy of one […]

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Efficacy and Safety of BNT162b2 mRNA Covid-19 Vaccine at 6 Months

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., … & Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. The New England Journal of Medicine, 385(19), 1761-1773. https://doi.org/10.1056/NEJMoa2110345 Summary: The BNT162b2 mRNA vaccine demonstrates high efficacy and safety against Covid-19,

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Summary of Public Health Scotland’s COVID-19 Statistical Report (Public Health Scotland – 2021)

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Public Health Scotland. (2021). COVID-19 statistical report: As at 18 October 2021. Retrieved from https://www.publichealthscotland.scot/ Summary: The Public Health Scotland COVID-19 Statistical Report, published on 20 October 2021, provides a comprehensive overview of COVID-19 incidence and related data in Scotland. As of 17 October 2021, there were 609,959 confirmed cases, with a notable decrease

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Breakthrough Infections of the Delta Variant Among Vaccinated Healthcare Workers

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Chau, N. V. V., Ngoc, N. M., Nguyet, L. A., Quang, V. M., Ny, N. T. H., Khoa, D. B., Phong, N. T., Toan, L. M., Dung, N. T., Yen, L. M., Thwaites, G., & Tan, L. V. (2021). An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam.

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Delta Variant’s Impact on Vaccinated Individuals

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: McCullough, P. (2021, September 20). Scientists: Delta infections of fully vaccinated produce 251 times the viral load. Technocracy News. https://www.technocracy.news/scientists-delta-infections-of-fully-vaccinated-produce-251-times-the-viral-load/ Summary: A recent study indicates that fully vaccinated individuals infected with the Delta variant carry viral loads 251 times higher than those infected with earlier strains of SARS-CoV-2. The research, conducted in a controlled

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Shedding of Infectious SARS-CoV-2 Despite Vaccination

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Riemersma, K. K., Haddock, L. A. III, Wilson, N. A., Minor, N., Eickhoff, J., Grogan, B. E., Kita-Yarbro, A., Halfmann, P. J., Segaloff, H. E., Kocharian, A., Florek, K. R., Westergaard, R., Bateman, A., Jeppson, G. E., Kawaoka, Y., O’Connor, D. H., Friedrich, T. C., & Grande, K. M. (2022). Shedding of infectious SARS-CoV-2

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Impact of the SARS-CoV-2 Delta Variant and Vaccine Efficacy

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Tareq, A. M., Bin Emran, T., Dhama, K., Dhawan, M., & Tallei, T. E. (2021). Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic. Human Vaccines & Immunotherapeutics, 17(11), 4126–4127. https://doi.org/10.1080/21645515.2021.1963601 Summary: The article examines the impact of the SARS-CoV-2 delta variant

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Update on SARS-CoV-2 Variants of Concern in England

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Public Health England. (2021). SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 17 (25 June 2021). Retrieved from https://www.gov.uk/phe Summary: The Technical Briefing 17 from Public Health England, dated 25 June 2021, reports on the surveillance of SARS-CoV-2 variants in England. As of that date, there are four variants of

COVID-19, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Viral illnesses

Improved Diagnosis of SARS-CoV-2 Using Nucleoprotein and Spike Protein Fragment in ELISA Tests

| | COVID-19, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Viral illnesses

Reference: De Marco Verissimo, C., O’Brien, C., López Corrales, J., Dorey, A., Cwiklinski, K., Lalor, R., … & Doyle, S. (2021). Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. Epidemiology and Infection, 149, e140, 1–11. https://doi.org/10.1017/S0950268821001308 Summary: The article discusses advancements in diagnosing SARS-CoV-2 through the

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Ethics, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Monitoring the Effectiveness of the Ad26.COV2.S COVID-19 Vaccine in South African Healthcare Workers

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Ethics, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: South African Medical Research Council. (2021). Sisonke Protocol Version 4.4 dated 29 Apr 2021. Summary: The Sisonke Protocol is an open-label, single-arm phase 3B study aimed at evaluating the effectiveness of the Ad26.COV2.S COVID-19 vaccine among healthcare workers in South Africa. This study involves approximately 500,000 healthcare workers aged 18 and older, who will

Scroll to Top